More help for patients with less severe heart failure
Abstract
Prescribe a mineralocorticoid-receptor antagonist for patients with New York Heart Association (NYHA) Class II systolic heart failure and an ejection fraction (EF) ≤30%. Eplerenone has been found to decrease hospitalizations for heart failure and cardiovascular and all-cause mortality. Stength of recommendation: A: Based on one high-quality randomized controlled trial (RCT).
Citation
Journal of Family Practice, 60(8) 2011: 482+.
Rights
OpenAccess.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.